📊 NRIX Key Takeaways
Is Nurix Therapeutics, Inc. (NRIX) a Good Investment?
Nurix Therapeutics is a pre-commercial stage pharmaceutical company with severe operating losses (-$285.7M) and negative free cash flow (-$263.5M), indicating the business model is not yet sustainable. While revenue growth of 54% YoY is positive and the balance sheet shows adequate liquidity ($247M cash, 7.02x current ratio), the company is burning cash at an unsustainable rate and lacks clear profitability visibility.
Nurix has strong liquidity (7.0x current ratio) and no debt, but fundamentals are challenged: operating losses (-340% margin) and heavy cash burn (-$263M FCF) dwarf its growing collaboration revenue. With ~$247M in cash and no commercial gross margin visibility, sustainability hinges on milestone payments and external financing, raising dilution risk if current R&D intensity persists. Risk/reward skews negative until there is clearer operating leverage or line-of-sight to commercialization.
Why Buy Nurix Therapeutics, Inc. Stock? NRIX Key Strengths
- Strong revenue growth of 54% year-over-year demonstrates market validation
- Adequate liquidity with $247M in cash equivalents and 7.02x current ratio
- No long-term debt, providing financial flexibility and reducing solvency risk
- Substantial asset base of $688.1M supports future operations
- Robust liquidity and no leverage (7.0x current, 0.00x D/E)
- Strong YoY revenue growth (+54%) from partnerships
- Solid equity base ($539M) supporting ongoing R&D
NRIX Stock Risks: Nurix Therapeutics, Inc. Investment Risks
- Extreme operating losses of -$285.7M with operating margin of -340% indicates pre-profitability stage
- Negative free cash flow of -$263.5M means company must continue burning through cash reserves
- At current burn rate, existing cash runway is approximately 12-14 months without additional financing
- Biotech/pharma sector requiring significant R&D investment before commercial viability
- Net loss widening on a percentage basis relative to revenue growth is unsustainable long-term
- High cash burn and deeply negative FCF implying limited runway
- Revenue reliance on milestones/collaborations with low visibility
- Likely need for additional capital and dilution amid persistent losses
Key Metrics to Watch
- Quarterly operating cash burn rate and cash runway remaining
- Revenue growth sustainability and pipeline advancement toward commercialization
- Gross margin upon achieving scale and operational leverage
- Path to EBITDA breakeven and timeline to profitability
- Cash and short-term investments (estimated runway months)
- Collaboration/deferred revenue trend and milestone receipt consistency
Nurix Therapeutics, Inc. (NRIX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 7.02x current ratio provides a solid financial cushion.
NRIX Profit Margin, ROE & Profitability Analysis
NRIX vs Healthcare Sector: How Nurix Therapeutics, Inc. Compares
How Nurix Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Nurix Therapeutics, Inc. Stock Overvalued? NRIX Valuation Analysis 2026
Based on fundamental analysis, Nurix Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Nurix Therapeutics, Inc. Balance Sheet: NRIX Debt, Cash & Liquidity
NRIX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Nurix Therapeutics, Inc.'s revenue has shown modest growth of 9% over the 5-year period. The most recent EPS of $-2.65 indicates the company is currently unprofitable.
NRIX Revenue Growth, EPS Growth & YoY Performance
NRIX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $6.3M | -$56.4M | $-0.67 |
| Q3 2025 | $7.9M | -$41.5M | $-0.67 |
| Q2 2025 | $12.1M | -$41.5M | $-0.52 |
| Q1 2025 | $16.6M | -$41.5M | $-0.67 |
| Q3 2024 | $12.6M | -$24.3M | $-0.67 |
| Q2 2024 | $12.1M | -$24.3M | $-0.45 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Nurix Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
NRIX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Nurix Therapeutics, Inc. (CIK: 0001549595)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NRIX
What is the AI rating for NRIX?
Nurix Therapeutics, Inc. (NRIX) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 72% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NRIX's key strengths?
Claude: Strong revenue growth of 54% year-over-year demonstrates market validation. Adequate liquidity with $247M in cash equivalents and 7.02x current ratio. ChatGPT: Robust liquidity and no leverage (7.0x current, 0.00x D/E). Strong YoY revenue growth (+54%) from partnerships.
What are the risks of investing in NRIX?
Claude: Extreme operating losses of -$285.7M with operating margin of -340% indicates pre-profitability stage. Negative free cash flow of -$263.5M means company must continue burning through cash reserves. ChatGPT: High cash burn and deeply negative FCF implying limited runway. Revenue reliance on milestones/collaborations with low visibility.
What is NRIX's revenue and growth?
Nurix Therapeutics, Inc. reported revenue of $84.0M.
Does NRIX pay dividends?
Nurix Therapeutics, Inc. does not currently pay dividends.
Where can I find NRIX SEC filings?
Official SEC filings for Nurix Therapeutics, Inc. (CIK: 0001549595) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NRIX's EPS?
Nurix Therapeutics, Inc. has a diluted EPS of $-3.05.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NRIX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Nurix Therapeutics, Inc. has a SELL rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NRIX stock overvalued or undervalued?
Valuation metrics for NRIX: ROE of -49.1% (sector avg: 15%), net margin of -314.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NRIX stock in 2026?
Our dual AI analysis gives Nurix Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NRIX's free cash flow?
Nurix Therapeutics, Inc.'s operating cash flow is $-249.5M, with capital expenditures of $14.0M. FCF margin is -313.7%.
How does NRIX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -314.9% (avg: 12%), ROE -49.1% (avg: 15%), current ratio 7.02 (avg: 2).